New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
11:21 EDTINO, VMW, PSEC, IRBT, ATHN, LXK, SHPG, CROX, CMGOptions with decreasing implied volatility
Options with decreasing implied volatility: INO SHPG IRBT CMG LXK PSEC CROX ATHN VMW
News For INO;SHPG;IRBT;CMG;LXK;PSEC;CROX;ATHN;VMW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 24, 2015
07:38 EDTPSECProspect Capital management to meet with Deutsche Bank
Subscribe for More Information
07:05 EDTSHPGShire acquires Meritage Pharma
Subscribe for More Information
February 23, 2015
16:27 EDTSHPGOn The Fly: Closing Wrap
Stocks on Wall Street began the session in negative territory and remained there for most of the session, with the Nasdaq the lone index to post a small gain. The Dow was weighed down by shares of Boeing (BA), which slid after the stock received a downgrade. There was little in the way of positive economic news, as the most notable report showed existing homes were lower than expected due to a shortage of inventory. The averages drifted for most of the session, as investors may be waiting on the sidelines ahead of tomorrow’s banking panel testimony by Fed Chair Janet Yellen. ECONOMIC EVENTS: In the U.S., the Chicago Fed national activity index rebounded to 0.13 in January, which was nearly in-line with expectations. Existing home sales dropped 4.9% to a 4.82M rate in January, which was much worse than the expected 1.8% drop to a 4.95M unit rate. In Europe, the Ifo Institute’s measure of German business confidence rose to 106.8 in February, which was up a tenth of a percentage point from the previous month but below the 107.7 consensus forecast. Also, the Bank of Israel became the latest central bank to cut rates this year, lowering its main interest rate to 0.1% from 0.25%. COMPANY NEWS: The shares of a number of health insurers rose after the Centers for Medicare and Medicaid Services, or CMS, issued preliminary 2016 Medicare Advantage rates. According to Credit Suisse, the rates were favorable for the insurers. Following the CMS announcement made late Friday, Humana (HUM) climbed $8.40, or 5.38%, to $164.52, UnitedHealth (UNH) rose $3.78, or 3.36%, to $116.40, and WellCare (WCG) gained $4.68, or 5.53%, to $89.30. MAJOR MOVERS: Among the notable gainers was PTC Therapeutics (PTCT), which jumped $9.77, or 17.7%, to $64.96 after Reuters said the company is working with financial advisers to explore a potential sale after receiving takeover interest from several companies including Shire (SHPG) and BioMarin (BMRN). Also higher was Valeant (VRX), which rose $25.49, or 14.71%, to $198.75 after the company agreed to buy Salix (SLXP) for $158 per share and also reported better-than-forecast earnings. Salix shares, however, fell $2.09, or 1.32%, to $155.76, as a report Friday from CNBC's David Faber telegraphed the deal and suggested Valeant could value Salix around $160 per share. Among the noteworthy losers was Spectrum Pharmaceuticals (SPPI), which dropped $1.18, or 15.82%, to $6.28 after a judge ruled that a drug which could compete with the company's Fusilev treatment does not infringe on the company's intellectual property. Also lower were shares of Boeing, which fell $3.57, or 2.26%, to $154.74 after the stock was downgraded to Sell from Neutral at Goldman Sachs. INDEXES: The Dow fell 23.60, or 0.13%, to 18,116.84, the Nasdaq gained 5.01, or 0.1%, to 4,960.97, and the S&P 500 slipped 0.64, or 0.03%, to 2,109.66.
12:53 EDTSHPGAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
12:29 EDTSHPGPTC Therapeutics exploring potential sale, Reuters reports
Subscribe for More Information
11:32 EDTCROXCrocs reorganizes regional business structure
Subscribe for More Information
10:45 EDTPSECOptions with increasing implied volatility
Subscribe for More Information
07:55 EDTSHPGJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
06:40 EDTCROXCrocs price target lowered to $10 from $13 at Piper Jaffray
Subscribe for More Information
February 22, 2015
18:04 EDTSHPGShire completes acquisition of NPS Pharma
Shire (SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals (NPSP) and the subsequent acquisition of NPS Pharma.The tender offer expired at 12:00 midnight, New York City time, at the end of Friday, February 20, and was not extended. As of the expiration of the tender offer, a total of approximately 88,869,118 common shares of NPS Pharma had been validly tendered and not withdrawn pursuant to the tender offer, representing approximately 81.7% of the outstanding common shares of NPS Pharma. All shares that were validly tendered and not withdrawn pursuant to the tender offer were accepted for payment. After the acceptance of shares that were validly tendered and not withdrawn pursuant to the tender offer, Shire completed the acquisition of NPS Pharma today through a merger of one of Shire's subsidiaries with and into NPS Pharma. In connection with the merger, all common shares of NPS Pharma that were not accepted for payment in the tender offer (excluding any shares held by NPS Pharma as treasury stock (other than any shares held in an NPS Pharma benefit plan) and any shares with respect to which the holders have properly demanded appraisal rights in accordance with Delaware law) were converted into the right to receive $46.00 per share in cash, without interest and less any applicable withholding taxes, the same price that will be paid for shares accepted for payment in the tender offer. Following completion of the merger, NPS Pharma became a wholly owned subsidiary of Shire and NPS Pharma's shares ceased to be traded on NASDAQ.
15:59 EDTSHPGValeant to buy Salix for $10.1B, FT says
Subscribe for More Information
February 20, 2015
10:30 EDTPSECOptions with decreasing implied volatility
Subscribe for More Information
09:23 EDTCROXGoldman sees select Apparel and Footwear opportunities due to FX risk
Goldman said translation currency exposure in the Apparel and Footwear has created volatility and opportunity to gain exposure to this theme. Goldman's analyst sees a positive near-term set-up for Nike (NKE) and Tiffany (TIF) and a negative set-up for Crocs (CROX) and Abercrombie & Fitch (ANF) and of upcoming earnings reports.
07:08 EDTSHPGAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
08:48 EDTVMWVMware to hold a conference call with Jefferies
Jefferies Analyst John DiFucci co-hosts a conference call to discuss the VMware vSphere 6 and VMware Integrated OpenStack (VIO) on February 19 at 12 pm. Webcast Link
06:13 EDTCROXCrocs volatility elevated into Q4 and outlook
Subscribe for More Information
February 18, 2015
07:38 EDTVMWVMware named a Franchise Pick at Jefferies
Subscribe for More Information
February 17, 2015
18:06 EDTSHPGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:13 EDTVMWPoint72 gives quarterly update on stakes
Subscribe for More Information
09:12 EDTSHPGShire multiple poised to expand, says SunTrust
SunTrust believes that Shire's rare disease unit will account for 40% of its 2020 sales, versus the company's estimate of about 35%. As a result, the firm expects the company's multiple to "re-rate." The firm thinks that the company's long-term growth outlook is underappreciated, and it keeps a $262 price target and Buy rating on the shares.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use